Pyrimethamine: Difference between revisions
ClaireLewis (talk | contribs) (Created page with "''Note: As of 2015, pyrimethamine is only available in the US through a special pharmacy program''<ref>https://aidsinfo.nih.gov/news/1604/notice-of-availability-of-pyrimethami...") |
(Restore original dosing content alongside dynamic SMW tables) |
||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
''Note: As of 2015, pyrimethamine is only available in the US through a special pharmacy program''<ref>https://aidsinfo.nih.gov/news/1604/notice-of-availability-of-pyrimethamine</ref> | ''Note: As of 2015, pyrimethamine is only available in the US through a special pharmacy program''<ref>https://aidsinfo.nih.gov/news/1604/notice-of-availability-of-pyrimethamine</ref> | ||
==Administration== | ==Administration== | ||
*Type: Antiparasitic, indicated for treatment and prophylaxis of [[Toxoplasmosis]] and [[malaria]] | *Type: [[Antiparasitic]], indicated for treatment and prophylaxis of [[Toxoplasmosis]] and [[malaria]] | ||
*Dosage Forms: | *Dosage Forms: | ||
*Routes of Administration: Oral | *Routes of Administration: Oral | ||
*Common Trade Names: | *Common Trade Names: | ||
==Adult Dosing== | ==Adult Dosing== | ||
*25-200mg PO (weekly or daily, depending on indication), in combination with other antimicrobials | *25-200mg PO (weekly or daily, depending on indication), in combination with other antimicrobials | ||
===Indications by Disease=== | |||
{{#ask: [[Has DrugName::Pyrimethamine]] [[Has Population::Adult]] | |||
|?Treats disease=Disease | |||
|?Has Dose=Dose | |||
|?Has Context=Context | |||
|format=table | |||
|limit=50 | |||
|mainlabel=- | |||
|headers=show | |||
|sort=Treats disease | |||
}} | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*1-3mg/kg PO | *1-3mg/kg PO | ||
===Indications by Disease=== | |||
{{#ask: [[Has DrugName::Pyrimethamine]] [[Has Population::Pediatric]] | |||
|?Treats disease=Disease | |||
|?Has Dose=Dose | |||
|?Has Context=Context | |||
|format=table | |||
|limit=50 | |||
|mainlabel=- | |||
|headers=show | |||
|sort=Treats disease | |||
}} | |||
==Special Populations== | ==Special Populations== | ||
| Line 41: | Line 67: | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:ID]] | |||
Latest revision as of 02:39, 20 March 2026
Note: As of 2015, pyrimethamine is only available in the US through a special pharmacy program[1]
Administration
- Type: Antiparasitic, indicated for treatment and prophylaxis of Toxoplasmosis and malaria
- Dosage Forms:
- Routes of Administration: Oral
- Common Trade Names:
Adult Dosing
- 25-200mg PO (weekly or daily, depending on indication), in combination with other antimicrobials
Indications by Disease
| Disease | Dose | Context |
|---|---|---|
| Toxoplasmosis | 200mg PO load then 50mg PO q24hrs x 4 weeks | Immunocompetent with Leucovorin and Sulfadiazine |
| Toxoplasmosis | 200mg PO load then 75mg PO q24hrs x 4-8 weeks | Immunosuppressed |
Pediatric Dosing
- 1-3mg/kg PO
Indications by Disease
| Disease | Dose | Context |
|---|---|---|
| Toxoplasmosis | 2mg/kg/day PO x 2 days then 1mg/kg/day x 2-6 months, then 1mg/kg MWF | Congenital/Pediatric |
Special Populations
- Pregnancy Rating: C
- Lactation risk: Infant risk minimal
- Renal dosing:
Contraindications
- Allergy to class/drug
- megaloblastic anemia due to folate deficiency
Adverse Reactions
Serious
- SJS, TEN
- Pancytopenia, leukopenia, thrombocytopenia, megaloblastic anemia
Common
- Rash
Pharmacology
- Half-life: 52-97 hours
- Metabolism: Hepatic
- Excretion:
Mechanism of Action
- Blocks protozoal dihydrofolate reductase, inhibiting nucleic acid synthesis